The stock of commercial-stage biotech Travere Therapeutics (NASDAQ: TVTX) barreled into the late holiday period in style. On ...

Learn more about whether Travere Therapeutics, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Travere Therapeutics (TVTX) just hit a fresh 52 week high after the FDA removed an advisory committee review and relaxed REMS monitoring for FILSPARI, sharpening focus on January’s FSGS approval ...

As of Wednesday, December 24, Travere Therapeutics, Inc.’s TVTX share price has surged by 17.75%, which has investors questioning if this is right time to sell.

If you are wondering whether Travere Therapeutics is still good value after its big rebound, you are not alone. This stock has quickly moved from recovery story to serious contender on many watchlists ...

Travere Therapeutics recently reached a new 52-week high after investors reacted to regulatory updates for its rare kidney disease therapy FILSPARI, including the removal of an FDA advisory committee ...

The devastating consequences of mucopolysaccharidosis II (MPS II), also called Hunter syndrome, may soon become preventable ...

Cantor Fitzgerald notes that Travere Therapeutics (TVTX) is up 15% following the announcement from Dimerix that the FDA, in written feedback, ...

Wayfair (NASDAQ:W) Chief Executive Officer Niraj Shah sold 151,024 shares of Class A Common Stock on December 23 and 26, 2025, generating approximately $15.1 million. The transactions occurred at ...

Roche's Japanese unit Chugai Pharma has reached a deal to buy Renalys Pharma, a company set up to bring therapies developed elsewhere to markets in Asia. Chugai is paying JP 15 billion ($98 million) ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm ...